In this webcast, G. Michael Lewitt, MD, centered the discussion on a patient with moderate-to-severe atopic dermatitis (AD) who had technically improved, but not in a way that held. Flares still broke through and itch never fully resolved. The consistent burdens of sleep disruption, visible disease, and ongoing management of symptoms remained. 

Key Takeaways 

“Moderate” doesn’t always reflect lived disease: Clinical measures like BSA and IGA can suggest control, even when patients continue to struggle with itch, visibility, or quality-of-life impact. 

Partial response can delay better decisions: Incremental improvement can create a false sense of progress, extending treatment cycles that don’t ultimately lead to stability. 

The cycle is familiar and persistent: Topicals, improvement, flare, escalation, repeat. Many patients move through this pattern without ever reaching consistent control. 

What’s Changing 

Stability is becoming the goal: The discussion moved toward consistency as an endpoint, fewer flares, less variability, and more durable control. 

Treatment burden matters more than we say: It’s not just whether something works, but how much effort it takes to maintain that control, for both patients and practices. 

Earlier escalation is part of the conversation: Waiting for repeated failure or worsening disease may not reflect how we want to manage AD moving forward. 

A Different Threshold for Action 

How long do we continue a cycle that isn’t getting someone to stability? And what signals are enough to change course? 

This session builds on the idea that AD management isn’t just about what we prescribe, but how we define success and how willing we are to adjust when that definition isn’t met. 

Please take a moment to share your thoughts in this brief survey. Your feedback helps shape future sessions. 

Learn more about lebrikizumab.